US FDA approves Biogen-Sage Therapeutics pill for postpartum depression

The U.S. Food and Drug Administration (FDA) on Friday approved Biogen (NASDAQ: ) and Sage Therapeutics' oral pill to treat postpartum depression (PPD (NASDAQ: )) in adults. The companies had sought the FDA's approval for the drug, Zurzuvae, to treat major depressive disorder (MDD), or clinical…#fda #biogen #zurzuvae #mdd #newdrugapplication
Source: Reuters: Health - Category: Consumer Health News Source Type: news